253 related articles for article (PubMed ID: 10186468)
1. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
3. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
[TBL] [Abstract][Full Text] [Related]
4. Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
[TBL] [Abstract][Full Text] [Related]
5. [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].
Dodel RC; Pepperl S; Köhne-Volland R; Szucs T; Werhahn KJ; Noachtar S; Oertel WH
Med Klin (Munich); 1996 Jul; 91(7):479-85. PubMed ID: 8756119
[TBL] [Abstract][Full Text] [Related]
6. Costs of drug treatment in Parkinson's disease.
Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
Dodel RC; Berger K; Oertel WH
Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
[TBL] [Abstract][Full Text] [Related]
8. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
[TBL] [Abstract][Full Text] [Related]
11. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
[TBL] [Abstract][Full Text] [Related]
12. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
[TBL] [Abstract][Full Text] [Related]
13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
14. Drug and treatment costs in Parkinson's disease patients in Sweden.
Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
[TBL] [Abstract][Full Text] [Related]
15. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
Cubo E; Martínez Martin P; González M; Frades B;
Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
[TBL] [Abstract][Full Text] [Related]
16. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
Prado M; Jamora RD
J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
[TBL] [Abstract][Full Text] [Related]
17. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
[TBL] [Abstract][Full Text] [Related]
18. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
20. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
